Your browser doesn't support javascript.
loading
The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG.
Dias, Hans F; Fu, Jessie Fanglu; Luck, Trevor G; Wolfe, Grace E; Hostetter, Emma R; Ng, Nathan C; Zheng, Hui; Kühtreiber, Willem M; Price, Julie C; Catana, Ciprian; Faustman, Denise L.
Afiliación
  • Dias HF; Massachusetts General Hospital, Boston, MA, 02116, USA.
  • Fu JF; Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02116, USA.
  • Luck TG; Massachusetts General Hospital, Boston, MA, 02116, USA.
  • Wolfe GE; Massachusetts General Hospital, Boston, MA, 02116, USA.
  • Hostetter ER; Massachusetts General Hospital, Boston, MA, 02116, USA.
  • Ng NC; Massachusetts General Hospital, Boston, MA, 02116, USA.
  • Zheng H; Statistics Department, Massachusetts General Hospital, Boston, MA, 02116, USA.
  • Kühtreiber WM; Harvard Medical School and Massachusetts General Hospital, Boston, MA, 02116, USA.
  • Price JC; Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02116, USA.
  • Catana C; Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02116, USA.
  • Faustman DL; Massachusetts General Hospital, Boston, MA, 02116, USA. dfaustman@mgh.harvard.edu.
Sci Rep ; 14(1): 17611, 2024 07 30.
Article en En | MEDLINE | ID: mdl-39080423
ABSTRACT
The Bacillus Calmette-Guérin (BCG) vaccine, which has been used for > 100 years to prevent tuberculosis, is well-established for bladder cancer treatment, and under study for neurological and autoimmune diseases. In patients with type 1 diabetes (T1D), BCG vaccinations have been shown in randomized clinical trials to gradually lower blood sugar to near normal levels. This effect appears to be driven by a BCG-induced shift in lymphoid cells' glucose metabolism from oxidative phosphorylation to aerobic glycolysis. The latter is a state of high glucose utilization that draws more glucose from the blood. Apart from blood, it is unknown whether BCG establishes residence in any organs and alters their glucose metabolism. In this two-year-long clinical trial in type 1 diabetics, we use positron emission tomography (PET) and x-ray computed tomography (CT) to map organs that increase their uptake of the glucose analogue 18F-fluorodeoxyglucose (18F-FDG) before versus after BCG vaccinations. We also injected BALB/c mice with BCG to test for the presence of BCG in various organs. Results from both studies point to the spleen as the dominant site for glucose uptake and BCG residence. The human spleen is significant because its 47% increase in 18F-FDG uptake by a large population of lymphocytes and monocytes might help to explain BCG's systemic lowering of blood glucose to near normal levels. Findings suggest that the spleen, triggered by BCG, assumes a critical role in systemic glucose regulation in the absence of a functional pancreas.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bazo / Glucemia / Vacuna BCG / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Diabetes Mellitus Tipo 1 Límite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bazo / Glucemia / Vacuna BCG / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Diabetes Mellitus Tipo 1 Límite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido